Semaglutide and tirzepatide microdoses differ mainly in how the drug acts. Semaglutide works on one receptor, GLP-1. Tirzepatide works on two, GIP and GLP-1. Neither has an FDA-approved microdosing schedule, and we found no trial comparing them at low doses. At Living+, semaglutide microdose is $127 a month and tirzepatide microdose is $149 a month, and a licensed provider decides which fits, if either.
The milligrams can mislead. Wegovy starts at 0.25 mg a week and Zepbound starts at 2.5 mg, a tenfold gap on paper. These are different molecules, so a bigger number on a tirzepatide vial says nothing about whether it is stronger than semaglutide. A dose only means something next to the data for that drug.
| Semaglutide | Tirzepatide | |
|---|---|---|
| How it acts | GLP-1 receptor agonist. One target. | GIP and GLP-1 receptor agonist. Two targets. |
| FDA-approved brands | Wegovy and Ozempic. Compounded semaglutide is not FDA-approved. | Zepbound and Mounjaro. Compounded tirzepatide is not FDA-approved. |
| Half-life on the brand label | About 1 week. | About 5 to 6 days. |
| Birth control pills | Ask your provider. | The label advises a non-oral or added barrier method. That covers 4 weeks after starting and each increase. |
| Microdose evidence | Limited. | Limited. |
| Living+ microdose price | $127 a month. Weekly injection. | $149 a month. Weekly injection. |
Does full-dose data tell you which semaglutide vs. tirzepatide microdose is better?
Full-dose data cannot answer that. The head-to-head trial people cite is SURMOUNT-5, published in the New England Journal of Medicine in 2025. It enrolled 751 adults with obesity and without type 2 diabetes. On the highest doses they could tolerate for 72 weeks, those taking tirzepatide lost an average of 20.2% of body weight, against 13.7% for those taking semaglutide.
That is a real result, and it is often stretched past what it tested. The trial used 10 mg or 15 mg of tirzepatide and 1.7 mg or 2.4 mg of semaglutide. It did not test a microdose or a compounded product, and we found no study showing that the gap holds at much lower doses. The honest position is that nobody knows whether it does.
Research on lower doses is limited for both. A 2026 commentary in Expert Opinion on Pharmacotherapy says high-quality evidence for microdosing either drug is essentially absent. So picking one on the strength of a friend’s result, or on a chart from a full-dose trial, rests on very little. A person who already tried one of these drugs should tell the provider how it went, including any reaction, since that history is real information about that person.
How do side effects compare at low doses?
We found no published head-to-head for that either. Both labels list stomach and bowel complaints as the most common problems, and both carry the same kinds of warnings on the thyroid, the pancreas, the gallbladder and the kidneys. Both labels say not to combine the drug with another GLP-1 medicine.
Half-life counts in one practical way, because these drugs clear slowly. The Wegovy label says semaglutide stays in circulation for about 5 to 7 weeks after a last dose, and it advises stopping at least 2 months before a planned pregnancy. A side effect may not end the day a person stops.
The tirzepatide birth control note in the table is easy to skip and should not be. It applies during the weeks after starting and after each dose increase, on the Zepbound label.
Whichever one is prescribed, the same rules on compounding apply. Some medications prescribed through Living+ are compounded. Compounded drugs are not FDA-approved, and they are not the same as Wegovy, Ozempic, Zepbound or Mounjaro. They are prescribed only when the provider determines an FDA-approved product is not clinically suitable and documents why.
Patients do not choose between these two at Living+. A provider reviews health history and other medicines, and may prescribe neither. The $22 a month between the plans is the one difference here anyone can measure today.
Prices were accurate at the time this was published.
Quick answers
Is a tirzepatide microdose stronger than a semaglutide microdose?
No one can say. Tirzepatide beat semaglutide at full doses in SURMOUNT-5, but that trial did not test microdoses or compounded products. Comparing milligrams across the two drugs does not work either, since they are different molecules.
Which has fewer side effects at a low dose?
There is no head-to-head evidence at microdose levels. Both labels list stomach and bowel problems as the most common side effects. A licensed provider can review your history and any past reaction to either drug.
Can I switch between a semaglutide and a tirzepatide microdose?
Only if a licensed provider decides to change your prescription. Both labels say not to combine these drugs with another GLP-1 medicine, so do not take the two together. Tell your provider what you have taken and when.
How much does each microdose plan cost at Living+?
Semaglutide microdose is $127 a month and tirzepatide microdose is $149 a month. Both are weekly injections and include labs and a 24/7 care team. Microdosing is not an FDA-approved dosing schedule.
Sources
- DailyMed: Wegovy prescribing information
- DailyMed: Zepbound prescribing information
- Tirzepatide as compared with semaglutide for the treatment of obesity, NEJM 2025
- MedlinePlus: Semaglutide injection
- MedlinePlus: Tirzepatide injection
- Beck and Clements, Considerations and challenges in microdosing of GLP-1-based receptor agonists, Expert Opin Pharmacother 2026
- FDA: Compounding and the FDA, questions and answers
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss
See what a Living+ plan costs and whether it fits.
Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Living+ is not affiliated with or endorsed by these companies.
